COMPASS Pathways plc announces financial results and business highlights for the first quarter 202 COMPASS Pathways has raised a total of $116.2M in funding over 3 rounds. Their latest funding was raised on Apr 27, 2020 from a Series B round. COMPASS Pathways is registered under the ticker FRA:5Y6 . Their stock opened with €35.50 in its Sep 25, 2020 IPO. COMPASS Pathways is funded by 11 investors Investors and others should note that the Company communicates with its investors and the public using its website (www.compasspathways.com), its investor relations website (ir.compasspathways.com), and on social media (LinkedIn), including but not limited to investor presentations and investor fact sheets, US Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information posted on these channels and websites could be deemed to be. COMPASS Pathways plc is a biopharma company pioneering the development of psilocybin therapy, with an initial focus on treatment-resistant depression (TRD), a subset of major depressive disorder (MDD), comprising 100 million patients who are not helped after two or more antidepressant treatments
Steve Schultz -- Senior Vice President, Investor Relations Thank you, operator, and welcome all of you, and thank you for joining us today for our first-quarter 2021 results call. Again, my name is.. Investor Relations; Optionsscheine; Portfolio; Forum Diskussionen; Historische Kurse ; Analysen; Bilanz & GuV; Knock-Outs; Handeln; Indexzugehörigkeit; Realtime Push ; Chartsignale; Dividende; Ab. To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time
Investor Contacts; Compass Group International B.V. Regulatory Statements; Compass Group Finance Netherlands B.V. May 2020 Placing Offer; 2021 Annual General Meeting; ESG and Sustainability > Our Strategy > Safety; Stakeholder Engagement ; Our Pillars > Health and Wellbeing; Environmental Game Changers; Better for the World > Responsible Sourcing > Animal Welfar Investors | Compass Group. Share Price: 1594.50p (-51.50) Who We Are. At a Glance. Strategy & Business Model. Vision & Values. Corporate Governance. Policies. Leadership Investors: Stephen Schultz, firstname.lastname@example.org, +1 401 290 7423. COMPASS PATHWAYS PLC Consolidated Balance Sheets (unaudited) (in thousands, except share and per share amounts COMPASS Pathways Tracy Cheung, email@example.com, +44 7966 309024 Amy Lawrence, firstname.lastname@example.org, +44 7813 777919. Westwicke (for investor enquiries Jetzt wird es geheimnisvoll an der Börse: Nach Compass Pathways bringt Kult-Investor Peter Thiel mit Palantir ein weiteres umstrittenes Unternehmen an den Markt! 28.09.2020, 10:00 Uhr EQS GROU
The Cannabis Investor is a leading social media outlet for Cannabis investment opportunities and breaking industry news But to understand COMPASS Pathways better, we need to consider many other factors. Be aware that COMPASS Pathways is showing 3 warning signs in our investment analysis, and 1 of those is. There are currently 1.9 million COMPASS Pathways stocks held short by investors - that's known as COMPASS Pathways's short interest. This figure is 4.3% up from 1.8 million last month. There are a few different ways that this level of interest in shorting COMPASS Pathways stocks can be evaluated. COMPASS Pathways's short interest ratio (SIR Investors and others should note that the Company communicates with its investors and the public using its website (www.compasspathways.com), its investor relations website (ir.compasspathways.com.
The company's listed phone number is 44 64 6905 3974 and its investor relations email address is email@example.com. The official website for COMPASS Pathways is www.compasspathways.com The call can be accessed by dialling (833) 665-0659 from the United States, +1 (914) 987-7313 internationally, and 0800 028 8438 from the UK, followed by the conference ID: 4498819. The call will.. COMPASS Pathways plc a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the first quarter. Founded in 2016, Compass Pathways is located on the outskirts of Karl Pilkington's stomping grounds - Manchester, England - where the company managed to raise just over $116 million in funding from around a dozen investors including Peter Thiel before going public
COMPASS Pathways granted two US patents. London, UK - 23 March 2021 COMPASS Pathways plc (Nasdaq: CMPS) (COMPASS), a mental health care company dedicated to accelerating patient access to. Investor Relations Stock Information. Data Provided by Refinitiv. Minimum 15 minutes delayed. Recent Webcast Jun 3, 2021 at 2:00 PM EDT Jefferies Virtual Healthcare Conference. Recent Presentation Apr 26, 2021. CytomX Virtual Investor Event - April 2021. Corporate Fact Sheet.
Why the Compass Pathway IPO Really Matters. There is one big reason for investors to pay close attention to the Compass Pathways IPO. Beyond the fact it is captivating the market and riding a. Source: Compass Pathways Investor Deck Financials Overview. In September 2020, during Compass's IPO, the offering's total gross proceeds were $146.6 million. As of September 30th, they hold $196. COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for.
COMPASS Pathways plc is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company's focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The team is pioneering the development of a new model of. Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which.
CMPS News: Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) 05/17/2021 04:06:26 PM. CMPS News: COMPASS Pathways ADS reports Q1 results. 05/13/2021 07:28:22 AM. CMPS News: COMPASS Pathways plc announces financial results and business highlights for the first quarter 2021. 05/13/2021 07:00:00 AM. Post New Msg COMPASS Pathways plc a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has reported further results from a phase I study showing. .71% on the last trading day (Friday, 11th Jun 2021), rising from $39.40 to $39.68. , and has now gained 6 days in a row.It is not often that stocks manage to gain so many days in a row, and falls for a day or two should be expected. During the day the stock fluctuated 3.63% from a day low at $38.60 to a day high of $40.00 Compass Pathways: Huge Growth Potential, But I'm Cautious Bill to legalize psychedelics in California to get full Senate vote - Marijuana Moment COMPASS Pathways ADS reports Q1 result Our vision is a world of mental wellbeing. www.compasspathways.com Availability of other information about COMPASS Pathways Investors and others should note that we communicate with our investors and the public using our website (www.compasspathways.com), our investor relations website (ir.compasspathways.com), and on social media (LinkedIn.
Investor Relations site Read about our most recent news and financial results, upcoming events and much more. View our latest interim results . and the Annual Report 2019/20 . See all reports. H1 2020/21. roadshow presentation. See our latest presentation. Subscribe to the latest published . financial information . Subscription. Shareholders, view your. personal share information. Shareholder. COMPASS Pathways' stock is owned by many different retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (2.00%), Victory Capital Management Inc. (1.77%), Falcon Edge Capital LP (0.67%), Logos Global Management LP (0.63%), Ikarian Capital LLC (0.57%) and Woodline Partners LP (0.48%) Biotech-Firma: Compass Pathways legt starken Börsenstart hin. Die Biotech-Firma, an der auch der deutsche Investor Christian Angermayer beteiligt ist, kommt bei den Anlegern gut an. Sie will mit Magic Mushrooms Depressi [...] Den ganzen Artikel lesen: Biotech-Firma: Compass Pathways legt sta...→ Noch mehr. handelsblatt.com. Compass Pathways legt starken Börsenstart hin. vor 247 Tagen.
Psychedelic company Compass Pathways plc (Nasdaq: CMPS) reported its financial results for the third quarter of 2020 and gave an update on recent progress across its business. The company reported a net loss of $16.6 million and essentially no income as the company is focused on research at this time. The company has cash of $196.5 million as of 30 September 2020, which is expected to fund. Zacks Industry Outlook Highlights: Avantor, Eurofins Scientific, GoodRx Holdings, Apollo Medical and COMPASS Pathways. Zacks Equity Research 04/29/2021 02:23 AM ET. 5 Top Medical Services Stocks to Beat COVID-Led Industry Challenges. Despite the severe challenges posed by the COVID-19 pandemic, higher demand for telemedicine, digital influence. Compass Pathways (CMPS) ADS. Compass Pathways (CMPS) Sell: $38.92 Buy: $39.07. Change: $0.08 (0.20%) Prices delayed by at least 15 minutes. | Switch to live prices. | Turn on streaming prices. Add.
COMPASS is a mental health care company. We are dedicated to accelerating patient access to evidence-based... We are dedicated to accelerating patient access to evidence-based... Proactive leads the world in up-to-the-minute, multi-media news provision, events organisation, investor relations management and investor research Psychedelic company Compass Pathways PLC ( CMPS) got off to a stellar start of trading on Friday, as investors hungry for the next new thing bought up shares. The U.K.-based mental health care. Compass Pathways (Nasdaq:CMPS), a revolutionary scientific emerging growth company, is about to launch its initial public offering (IPO) on the Nasdaq stock exchange. It has the full endorsement and backing of Billionaire Peter Thiel, who owns 7.5% of the company. Compass began four years ago with the mission and motivation to discover better ways to [
COMPASS Pathways plc announces financial results and business highlights for the first quarter 2021 LONDON, May 13, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (COMPASS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the first quarter 2021 and gave an update on. Compass is backed by FF Angel, the early-stage investing arm of Founders Fund. Companies the firm has backed include Facebook, Quantcast, SpaceX, Spotify, RoboteX, and ZocDoc. The firm, which pursues a founder-friendly investment strategy, is managed by four partners, all of whom are themselves company founders: Peter Thiel (PayPal; Palantir); Ken Howery (PayPal); Luke Nosek (PayPal); and Sean. Availability of other information about COMPASS Pathways. Investors and others should note that the Company communicates with its investors and the public using its website (www.compasspathways.com), its investor relations website (ir.compasspathways.com), and on social media (LinkedIn), including but not limited to investor presentations and investor fact sheets, US Securities and Exchange. Compass Diversified Q1 2021 Earnings Conference Call. Webcast. (opens in new window) Investor Presentation. (opens in new window) Feb 24, 2021
COMPASS Pathways appoints Wayne J Riley MD to its Board of Directors . London, UK - 1 April 2021 COMPASS Pathways plc (NASDAQ:CMPS) (COMPASS), a mental health care company dedicated to. Although we expect Compass Pathways to proactively diversify its therapeutic pipeline in the coming months—as referenced in Form F1—the company has yet to go shopping. With $67.6 million in cash & cash equivalents as of June 30, 2020—plus total gross proceeds of $146.6 million in relation to its September IPO offering—Compass is bubbling with potential acquisition capital Investor Relations; This page shows the institutions and funds most likely to invest in CMPS / COMPASS Pathways Plc American Depository Shares, based on analysis of their current holdings. This information is useful to management and investor relations teams of publicly traded companies who wish to increase institutional investment in their.
Mushrooms work their magic as investors support Compass Pathways start-up. Simon Duke, Technology Business Editor. Monday April 27 2020, 12.01am, The Times. George Goldsmith and Ekaterina. Christian Angermayer holds 22% stake in Compass Pathways German investor's ATAI Life Sciences may go public in 2021 LISTEN TO ARTICLE. 3:03. SHARE THIS ARTICLE. Share. Tweet. Post. Email. Since the Compass Pathways NASDAQ IPO in Mid-September, Psychedelic Stocks Have Gone on an Absolute Tear Racking Up Eye-Popping Gains in the Process As We Approach the End of 2020,... read more → December 14, 202 News that COMPASS Pathways is attempting to patent psychedelic therapy room specifications and therapist behaviors started an online firestorm about the company's monopolistic and shady behaviors, but so far the debates have missed the biggest threats lurking in COMPASS's international patent applications At Compass Diversified, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the 'unsubscribe' section below. If you experience any issues with this process, please contact us for further assistance
Compass Minerals produces salt, plant nutrients and magnesium chloride for distribution primarily in North America. We also provide secure records storage in a retired mine in the U.K. Products from Compass Minerals serve a variety of applications in industrial, agricultural, commercial and consumer markets The Investor Relations website contains information about Comcast Corporation's business for stockholders, potential investors, and financial analysts
VP Corporate Development and Investor Relations. Chris Evans. Investor Relations Director. Lori Ursomarso. Investor Relations Specialist +1.302.773.2263 firstname.lastname@example.org. Email Alerts. Receive the latest news and information via email. Email Address * Mailing Lists * Press Releases: Events: SEC Filings: End-of-Day Stock Quote : Presentations: Financials : Enter the code shown above. Compass Pathways Leads the Way as the First Psychedelics Company to IPO on the Nasdaq. September 24, 2020 (MicroSmallCap via Comtex) — Last year may have been all about cannabis, but it's clear that 2020 and beyond belongs to the psychedelic medicine market. Ever since Johnson & Johnson's ( NYSE:JNJ) ketamine-derived medicine, Spravato. Investor Information. These documents contain selected important information to help you make informed investment decisions and understand your rights as an investor. For your convenience, you may also sign up to receive email notifications when new reports for a fund you hold or are interested in become available
Investor Contact: Transfer Agent: Gregory A. Riddle Vice President, Investor Relations Five Penn Plaza 19th Floor New York, NY 10001 1 (212) 835-1620 email@example.com. American Stock, Transfer & Trust Company 1-800-937-5449 www.amstock.co Atom Investors LP closes position in CMPS / Compass Pathways Plc. 2021-05-17 - Atom Investors LP has filed a 13F-HR form disclosing ownership of 0 shares of Compass Pathways Plc (GB:CMPS) with total holdings valued at $0 USD as of 2021-03-31. Atom Investors LP had filed a previous 13F-HR on 2021-02-16 disclosing 20,069 shares of Compass Pathways Plc at a value of $956,000 USD. This represents. Compass Investor Relations was established by four veteran IR professionals. Our founding partners have a combined 40 years of investor relations experience that will give you the best possible support in the public markets. Our programs are focused on executing best-practices investor relations designed to increase awareness of the stock among buy-side and sell-side investors, reach and. A global leader in aeronautics, space and related services, Airbus has a robust and diverse backlog and a clear focus on ramp-up, execution, profitability, value creation and market positioning. We are committed to increasing shareholder returns. We target sustainable growth in our dividend, with a payout ratio of 30-40%, and have simplified.
Compass Pathways PLC raised about $146.6 million in gross proceeds via its IPO on the Nasdaq Global Select Market.. The British pharmaceutical company, which focuses on mental health treatments, sold a total of 8,625,000 American depositary shares in the offering, including 1,125,000 ADSs sold as underwriters fully exercised their overallotment option Featuring Presentations directly from Executives of issuing companies. Filter by Underwriter... Current Shows. There are no active RetailRoadshows available at this time. Over 2000 IPOs including..
LONDON, April 27, 2020 /CNW/ -- COMPASS Pathways, a mental health care company, announced today that it has completed a successful $80m Series B investment round. This funding will expand upon. COMPASS Pathways plc announces financial results and business highlights for the first quarter 2021. 05/13 07:00. Yahoo. Compass Pathways Plc - ADR to Host Earnings Call . 05/13 05:45. MT Newswires--Cantor Fitzgerald Initiates Compass Pathways at Overweight Rating With $71 Price Target. 05/11 08:57. Yahoo. COMPASS Pathways plc to announce first quarter 2021 financial results on 13 May 2021. 05.
DALLAS, Aug. 1, 2019 /PRNewswire/ -- Southwest Airlines Co. (NYSE: LUV) today launches an innovative career program called Destination 225° which provides pathways to becoming a competitively qualified candidate for future Southwest First Officer positions. On a compass, 225° is the southwest directional heading, and Destination 225° was developed to lead aspiring Pilots to Southwest Airlines Compass Pathways Offers Chance on Exploratory Mental Health Treatments. As a treatment for mood disorders, psychedelics-inspired medicine isn't quite in the mainstream yet. Undoubtedly, Compass. Grizzle identified Compass Pathways as our conviction call IPO, our primer laid out the opportunity (Sept 18/2020). The stock's IPO price was $17 and opened at $23.40 (the price retail investors could get in at), the share price has since run to $40 - a return of 70% Compass Pathways CEO George Goldsmith set out his plans for the future of psilocybin - the active compound found in magic mushrooms that the Nasdaq-listed company is trialing as a treatment for severe depression Expertise: Corporate strategy, corporate and business development, in- and out-licensing, change programmes, M&A, Investor Relations, IT, Finance and Legal functions. Activity Can we see some posts thanking Matt Hancock and his leadership. Taking the 100k per day testing target as an example he was brave to push our sector Liked by Piers Morgan. Experience CFO COMPASS Pathways plc (Nasdaq.